journal article·2024-12

“Internal Trouble and Outside Aggression” Strategy: Energy Deprivation Synergized With cGAS‐STING Pathway Activation for Stimuli‐Responsive Photodynamic‐Metal‐Metabolic Immunotherapy

Yanrong Qian, Yulin Xie, Guoqing Zhu, Man Wang, Junrong Wang, Qianqian Sun, Jun Lin, Chunxia Li

Advanced Functional Materials· Volume 34· Issue 51
Publisher page

Abstract

Abstract The aberrant metabolic activities of tumor cells not only facilitate tumor proliferation but also impair immune cell function and cause an immunosuppressive tumor microenvironment (TME). Thus, reshaping the metabolic TME while activating innate immunity is highly desirable but challenging. Herein, a multifunctional immunomodulator is engineered for near‐infrared light (NIR)‐triggered photodynamic‐metal‐metabolic immunotherapy via the “internal trouble and outside aggression” strategy. Specifically, an endogenous and exogenous stimuli‐responsive nanoagent is prepared consisting of photosensitizer chlorin e6 (Ce6) modified dense silica‐coated rare earth‐doped nanoparticles (ReNPs@SiO2(Ce6)), with in situ grown ZIF‐8 on the surface for loading glucose transporter‐1 (GLUT‐1) inhibitor Fasentin and glutaminase‐1 inhibitor bis‐2‐(5‐phenylacetamido‐1,3,4‐thiadiazol‐2‐yl)ethyl sulfide (BPTES). The as‐obtained final product is denoted as ReSZ(FB). ReSZ(FB) induces‐ mitochondrial damage and releases mitochondrial DNA (mtDNA) via NIR‐mediated PDT. Subsequently, Zn2+ from ZIF‐8 collaborates with mtDNA to activate the cGAS‐STING pathway, initiating a robust tumor‐specific immune response. Concurrently, Fasentin and BPTES triggeres energy deprivation by blocking glucose uptake and inhibiting glutamine decomposition, thereby reprogramming the metabolic TME, and alleviating immunosuppression. Tumor cells are damaged and trapped into “internal trouble” by combining PDT and energy deprivation, while the sharply enhanced immune cell lethality exposes cancer cells to “outside aggression”. Overall, this photodynamic‐metal‐metabolic immunotherapy provides a promising paradigm for cancer therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: interferon and immune responses · Nanoplatforms for cancer theranostics · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Frontier Chemistry School of Chemistry and Chemical Engineering Shandong University Qingdao 266237 P. R. China

State Key Laboratory of Rare Earth Resource Utilization Changchun Institute of Applied Chemistry Chinese Academy of Sciences Changchun 130022 P. R. China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Shandong Province · Taishan Scholar Foundation of Shandong Province

References (92)

Show source-provided references
1. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
2. 10.1038/s41422-020-0337-210.1038/s41422-020-0337-2 ↗
3. 10.1038/s41577-019-0218-410.1038/s41577-019-0218-4 ↗
4. 10.1093/eurheartj/ehac10610.1093/eurheartj/ehac106 ↗
5. 10.1016/j.canlet.2023.21607410.1016/j.canlet.2023.216074 ↗
6. 10.1021/acsnano.3c1238710.1021/acsnano.3c12387 ↗
7. 10.1002/cac2.1225510.1002/cac2.12255 ↗
8. 10.1186/s13045-022-01282-810.1186/s13045-022-01282-8 ↗
9. 10.1021/jacs.3c1400510.1021/jacs.3c14005 ↗
10. 10.1038/s41568-024-00714-610.1038/s41568-024-00714-6 ↗
11. 10.1016/j.cell.2022.06.03510.1016/j.cell.2022.06.035 ↗
12. 10.1038/s41573-018-0007-y10.1038/s41573-018-0007-y ↗
13. 10.1038/s41563-021-01047-710.1038/s41563-021-01047-7 ↗
14. 10.1002/adma.20230424610.1002/adma.202304246 ↗
15. 10.1002/smll.20230845610.1002/smll.202308456 ↗
16. 10.1002/adfm.20240127210.1002/adfm.202401272 ↗
17. 10.1002/adma.20240041610.1002/adma.202400416 ↗
18. 10.1002/adma.20221133710.1002/adma.202211337 ↗
19. 10.1002/advs.20230787010.1002/advs.202307870 ↗
20. 10.1002/anie.20231907310.1002/anie.202319073 ↗
21. 10.1021/jacs.9b1278810.1021/jacs.9b12788 ↗
22. 10.1016/j.ctrv.2021.10222710.1016/j.ctrv.2021.102227 ↗
23. 10.1038/s41571-019-0272-710.1038/s41571-019-0272-7 ↗
24. 10.1021/acsnano.1c0963510.1021/acsnano.1c09635 ↗
25. 10.1002/smtd.20220140310.1002/smtd.202201403 ↗
26. 10.1021/jacs.3c0123110.1021/jacs.3c01231 ↗
27. 10.1002/adfm.20240148910.1002/adfm.202401489 ↗
28. 10.1002/adfm.20190244010.1002/adfm.201902440 ↗
29. 10.1021/acsnano.2c0085410.1021/acsnano.2c00854 ↗
30. 10.1002/adma.20200356310.1002/adma.202003563 ↗
31. 10.1002/adma.20210601010.1002/adma.202106010 ↗
32. 10.1002/adma.20230356710.1002/adma.202303567 ↗
33. 10.1002/advs.20190169010.1002/advs.201901690 ↗
34. 10.1002/adom.20230080210.1002/adom.202300802 ↗
35. 10.1021/acsnano.3c0330810.1021/acsnano.3c03308 ↗
36. 10.1021/acs.nanolett.8b0004010.1021/acs.nanolett.8b00040 ↗
37. 10.1002/adma.20230641910.1002/adma.202306419 ↗
38. 10.1021/acsnano.3c0400210.1021/acsnano.3c04002 ↗
39. 10.1002/advs.20230738910.1002/advs.202307389 ↗
40. 10.1002/advs.20230296710.1002/advs.202302967 ↗
41. 10.1002/adma.20231302910.1002/adma.202313029 ↗
42. 10.1021/acs.nanolett.3c0100810.1021/acs.nanolett.3c01008 ↗
43. 10.1016/j.nantod.2024.10223110.1016/j.nantod.2024.102231 ↗
44. 10.1002/adma.20230484510.1002/adma.202304845 ↗
45. 10.1002/bmm2.1207710.1002/bmm2.12077 ↗
46. 10.1016/j.nantod.2023.10183110.1016/j.nantod.2023.101831 ↗
47. 10.1038/s41467-023-40345-310.1038/s41467-023-40345-3 ↗
48. 10.1038/s41556-022-01002-x10.1038/s41556-022-01002-x ↗
49. 10.1038/s41571-019-0203-710.1038/s41571-019-0203-7 ↗
50. 10.1016/j.addr.2022.11424210.1016/j.addr.2022.114242 ↗
51. 10.1021/acs.bioconjchem.8b0006810.1021/acs.bioconjchem.8b00068 ↗
52. 10.1002/adma.20230909410.1002/adma.202309094 ↗
53. 10.1038/s41577-019-0140-910.1038/s41577-019-0140-9 ↗
54. 10.1038/s41577-024-01026-410.1038/s41577-024-01026-4 ↗
55. 10.1038/s41467-023-42883-210.1038/s41467-023-42883-2 ↗
56. 10.1002/anie.20240239710.1002/anie.202402397 ↗
57. 10.1021/acsnano.3c0242810.1021/acsnano.3c02428 ↗
58. 10.1021/acsnano.3c0174310.1021/acsnano.3c01743 ↗
59. 10.1002/advs.20220480810.1002/advs.202204808 ↗
60. 10.1016/j.biomaterials.2023.12208910.1016/j.biomaterials.2023.122089 ↗
61. 10.1021/acsnano.2c1103710.1021/acsnano.2c11037 ↗
62. 10.1016/j.actbio.2022.12.05210.1016/j.actbio.2022.12.052 ↗
63. 10.1021/jacs.4c0347810.1021/jacs.4c03478 ↗
64. 10.1016/j.cell.2018.10.00110.1016/j.cell.2018.10.001 ↗
65. 10.1038/s41586-023-06299-810.1038/s41586-023-06299-8 ↗
66. 10.1016/j.jconrel.2023.04.02710.1016/j.jconrel.2023.04.027 ↗
67. 10.1002/adhm.20210203810.1002/adhm.202102038 ↗
68. 10.1002/anie.20241024110.1002/anie.202410241 ↗
69. 10.1002/smll.20230570810.1002/smll.202305708 ↗
70. 10.1002/adhm.20230108710.1002/adhm.202301087 ↗
71. Qian Y. · Small Methods · 2023 · 7
72. Wang Q.‐X. · Nano Today · 2022 · 43
73. 10.1002/adma.20210012910.1002/adma.202100129 ↗
74. 10.1039/C4CS00155A10.1039/C4CS00155A ↗
75. 10.1039/C8NR00446C10.1039/C8NR00446C ↗
76. 10.1002/lpor.20220053110.1002/lpor.202200531 ↗
77. 10.1002/anie.20170301210.1002/anie.201703012 ↗
78. 10.1021/acs.chemmater.9b0478410.1021/acs.chemmater.9b04784 ↗
79. 10.1002/adma.20160543410.1002/adma.201605434 ↗
80. 10.1038/s41467-023-36813-510.1038/s41467-023-36813-5 ↗
81. 10.1002/anie.20220048010.1002/anie.202200480 ↗
82. 10.1002/adfm.20231241610.1002/adfm.202312416 ↗
83. 10.1021/acsnano.2c0581810.1021/acsnano.2c05818 ↗
84. Wang Y. · Nat. Sci. Rev. · 2021 · 8
85. 10.1038/s41556-023-01185-x10.1038/s41556-023-01185-x ↗
86. 10.1158/0008-5472.CAN-17-301810.1158/0008-5472.CAN-17-3018 ↗
87. 10.1084/jem.2012016210.1084/jem.20120162 ↗
88. 10.3390/cancers1201015410.3390/cancers12010154 ↗
89. 10.1021/acsnano.3c0316910.1021/acsnano.3c03169 ↗
90. 10.1016/j.cej.2022.13478110.1016/j.cej.2022.134781 ↗
91. 10.1016/j.biomaterials.2024.12247210.1016/j.biomaterials.2024.122472 ↗
92. 10.1002/adma.20220686110.1002/adma.202206861 ↗